As we pass the midway point of the calendar year and begin the new financial year, here are two ASX 100 shares to watch.
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL is the largest ASX healthcare stock by market capitalisation.
The Australian-based global biotechnology company develops and delivers biotherapies and vaccines.
Its share price is down almost 20% over the last 12 months.
It has faced several headwinds including low revenue growth, tariff threats and cuts to research and development.
Despite all these red flags, the narrative surrounding this ASX 100 stock is that the rebound is coming.
But when?
Many brokers have attractive price targets on the ASX healthcare stock.
In fact, according to Trading View, 13 analysts have price targets between $283.38 and $354.20.
This indicates upside of between14% and 43%.
This messaging infers it's a matter of "when" not "if" for CSL. However holders of the stock over the past year may feel they have heard this before.
Regardless, it can be rare for a blue-chip stock to be this significantly undervalued.
Xero Ltd (ASX: XRO)
It's been a different story for Xero over the past 12 months..
The cloud-based, accounting software company has seen its share price grow 25% in the last year.
The share price hit an all-time high in June before sinking after it completed its fully underwritten institutional placement and acquisition of payments platform Melio.
Since then, it has fallen roughly 9%.
It seems investors were either profit taking or less optimistic than the company after this acquisition.
On the other hand, Macquarie saw it as a positive, saying investors should take advantage of any share price weakness.
The broker has a $204.00 price target on Xero's shares.
Bell Potter has a price target of $204.13
This is roughly a 15% upside.
Growth shares can be tricky to value, as one school of thought may believe this is just the beginning for Xero, whilst other investors may look at 25% rise over the last year and think they've missed the boat already.
Foolish takeaway
These two ASX 100 shares are poised in very different positions.
CSL is a blue-chip holding with a proven track record. The consensus points towards a quality option that is undervalued based on very real headwinds. Those happy to play the long game may reap the rewards down the track.
On the other hand, Xero is a growth share that has recently hit an all-time high. This can make it difficult to jump in now, but price targets suggest it has further potential.
